{"filing":{"accession_number":"0001171843-26-004635","cik":"0000898437","ticker":"ANIK","company_name":"Anika Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"f8k_071426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184326004635/f8k_071426.htm"},"events":[{"id":17922,"run_id":16075,"accession_number":"0001171843-26-004635","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"Anika Therapeutics entered into a Fifth Amendment to its revolving credit agreement with Bank of America on July 10, 2026, establishing a $50.0 million senior revolving line of credit with a maturity date of July 10, 2031, and an option to request up to an additional $50.0 million for a maximum of $100.0 million.","company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16576,"accession_number":"0001171843-26-004635","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Anika Therapeutics entered into a Fifth Amendment to its revolving credit agreement with Bank of America on July 10, 2026, amending the existing facility dated October 24, 2017. The Amended Agreement establishes a $50.0 million senior revolving line of credit with a maturity date of July 10, 2031, with an option to request up to an additional $50.0 million for a maximum of $100.0 million. This constitutes creation or material amendment of a direct financial obligation under Item 1.01, fitting the debt_issuance category as it involves entry into a material definitive credit facility agreement with specified terms, interest rates (SOFR plus 0.25%-1.25%), commitment fees, and financial covenants.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T21:01:38.458012+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16577,"accession_number":"0001171843-26-004635","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 is the dedicated disclosure item for creation of direct financial obligations, typically debt issuances. The section incorporates Item 1.01 by reference, which commonly covers material acquisitions or transactions that create new debt obligations. The materiality and specificity of Item 2.03 filing indicates a significant financial obligation was created.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T21:01:38.458012+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16576,"accession_number":"0001171843-26-004635","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Anika Therapeutics entered into a Fifth Amendment to its revolving credit agreement with Bank of America on July 10, 2026, amending the existing facility dated October 24, 2017. The Amended Agreement establishes a $50.0 million senior revolving line of credit with a maturity date of July 10, 2031, with an option to request up to an additional $50.0 million for a maximum of $100.0 million. This constitutes creation or material amendment of a direct financial obligation under Item 1.01, fitting the debt_issuance category as it involves entry into a material definitive credit facility agreement with specified terms, interest rates (SOFR plus 0.25%-1.25%), commitment fees, and financial covenants.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T21:01:38.458012+00:00","company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","filing_date":"2026-07-14"},{"id":16577,"accession_number":"0001171843-26-004635","item_number":"2.03","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"Item 2.03 is the dedicated disclosure item for creation of direct financial obligations, typically debt issuances. The section incorporates Item 1.01 by reference, which commonly covers material acquisitions or transactions that create new debt obligations. The materiality and specificity of Item 2.03 filing indicates a significant financial obligation was created.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T21:01:38.458012+00:00","company_name":"Anika Therapeutics, Inc.","ticker":"ANIK","filing_date":"2026-07-14"}]}